LEXINGTON, Mass., Jan. 24, 2018 /PRNewswire/ -- Pulmatrix,
Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company
developing innovative inhaled therapies to address serious
pulmonary diseases announced today that it will present new
preclinical data for Pulmazole (PUR1900), its inhaled antifungal
drug, in a poster at the 8th Advances Against Aspergillosis
Conference in Lisbon,
Portugal.
In a preclinical model of invasive aspergillosis, Pulmazole
treatment by inhalation resulted in a significant prolongation
of survival and improved clinical signs of infection compared to
placebo treatment. "The preclinical efficacy data highlights
the potential advantages of Pulmazole in treating pulmonary
Aspergillus infections by delivering itraconazole directly
to the lungs," said David Hava,
Ph.D., Chief Scientific Officer for Pulmatrix.
Pulmazole is being developed as a treatment of allergic
bronchopulmonary aspergillosis (ABPA) in patients with asthma and
was recently granted regulatory approval for the initiation of a
Phase 1/1b clinical trial in the
first quarter of 2018.
ABPA is a disease that occurs most often in patients with
underlying asthma or cystic fibrosis, and it is characterized by an
exaggerated allergic hypersensitivity response of the immune system
to the fungus Aspergillus growing in the airways. Oral
itraconazole (Sporanox®) is currently used as an adjunctive
treatment to corticosteroids in ABPA patients, however its use is
limited by poor bioavailability, variable pharmacokinetics, and
toxicity concerns related primarily to the risk of gastrointestinal
and cardiac side effects and extensive drug-drug interactions.
Pulmatrix's inhaled drug Pulmazole, which combines itraconazole
with the company's iSPERSE™ dry powder delivery technology, has the
potential to solve these problems by delivering the drug directly
to the lungs. The new study supports the potential advantages
of inhaled drug delivery, and extends previous preclinical results
demonstrating that administration of inhaled itraconazole can
result in higher levels in the lung relative to oral
itraconazole.
"The presentation of important preclinical data on the efficacy
of Pulmazole furthers our understanding of the potential of
Pulmazole to treat pulmonary infections caused by
Aspergillus in patients with underlying respiratory disease.
We are pleased that we have made significant advances in the
Pulmazole program and that we are poised to initiate clinical
testing," explained Robert Clarke,
Ph.D., Chief Executive Officer for Pulmatrix.
The poster will be presented during the conference in the Lisboa
Congress Centre in Lisbon,
Portugal, February 1 – 3,
2018. A copy of the poster will be available on the Pulmatrix
website following the meeting.
About
Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing
innovative inhaled therapies to address serious pulmonary disease
using its patented iSPERSE™ technology. The Company's proprietary
product pipeline is focused on advancing treatments for serious
lung diseases, including Pulmazole (PUR1900), an inhaled
anti-fungal for patients with ABPA, and PUR1800, a narrow spectrum
kinase inhibitor for patients with obstructive lung diseases
including asthma and COPD. In addition, Pulmatrix has partnered
with Vectura Group plc to develop Pulmatrix's drug candidate,
PUR0200, for COPD for the U.S. market. Pulmatrix's product
candidates are based on iSPERSE™, its proprietary engineered dry
powder delivery platform, which seeks to improve therapeutic
delivery to the lungs by maximizing local concentrations and
reducing systemic side effects to improve patient outcomes.
FORWARD-LOOKING STATEMENTS
Certain statements in this
press release that are forward-looking and not statements of
historical fact are forward-looking statements within the meaning
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The Company cautions that such statements
involve risks and uncertainties that may materially affect the
Company's results of operations. Such forward-looking statements
are based on the beliefs of management as well as assumptions made
by and information currently available to management. Actual
results could differ materially from those contemplated by the
forward-looking statements as a result of certain factors,
including but not limited to the ability to establish that
potential products are efficacious or safe in preclinical or
clinical trials; the ability to establish or maintain
collaborations on the development of therapeutic candidates; the
ability to obtain appropriate or necessary governmental approvals
to market potential products; the ability to obtain future funding
for developmental products and working capital and to obtain such
funding on commercially reasonable terms; the Company's ability to
manufacture product candidates on a commercial scale or in
collaborations with third parties; changes in the size and nature
of competitors; the ability to retain key executives and
scientists; and the ability to secure and enforce legal rights
related to the Company's products, including patent protection. A
discussion of these and other factors, including risks and
uncertainties with respect to the Company, is set forth in the
Company's filings with the Securities and Exchange Commission,
including its annual report on Form 10-K filed by the Company with
the Securities and Exchange Commission on March 10, 2017, as may be supplemented or amended
by the Company's Quarterly Reports on Form 10-Q. The Company
disclaims any intention or obligation to revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as required by law.
Investor
Contact
|
|
Robert Clarke,
CEO
|
William Duke,
CFO
|
(781)
357-2333
|
(781)
357-2333
|
rclarke@pulmatrix.com
|
wduke@pulmatrix.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/pulmatrix-will-present-pulmazole-preclinical-data-at-the-8th-advances-against-aspergillosis-conference-to-be-held-february-1---3-2018-300587585.html
SOURCE Pulmatrix, Inc.